Hello from Greycoat Research,

One protein has become increasingly important in feline kidney research: AIM (Apoptosis Inhibitor of Macrophages).

The role of AIM in feline kidney disease was first described by Toru Miyazaki.
His research suggested that cats have species-specific differences in AIM activity. This biological difference may help explain why chronic kidney disease (CKD) is common in cats.

Since then, research on AIM has continued to expand.

A Recent Study on AIM Genetics

A recently published study,
Apoptosis Inhibitor of Macrophages in Cats: A Potential Link Between an Exon 3 Variant Allele and Progression of Naturally Occurring Chronic Kidney Disease,

 examines a possible association between a specific Exon 3 variant of the AIM gene and the progression of naturally occurring CKD in cats.

In simple terms:

Some cats may be born with genetic variations that influence how AIM functions. These inherited traits may influence disease progression.

This does not mean genetics alone determines outcomes. However, it opens the possibility of identifying biological risk patterns earlier than before.

What This Means for the Future

With genetic screening methods, including simple oral swab sampling, it may become possible to assess whether a cat carries certain AIM-related genetic variants.

In the future, guardians may be able to:

• Understand potential genetic risk patterns earlier
• Consider earlier and more structured kidney care strategies

What Greycoat Research Is Preparing

Greycoat Research is currently preparing to introduce genetic testing as part of our ongoing research in feline kidney care.

Emerging research suggests that certain AIM gene variants may be associated with differences in disease progression and, in some cases, with a higher-risk profile.

Our goal is to help guardians recognize potential risk patterns at an early stage and make informed care decisions before significant clinical decline occurs.

Depending on the type and extent of genetic variation, we are also preparing to develop more structured and individualized care planning approaches.

We will share further details as development progresses.

What Can Be Done Now?

Even before genetic testing becomes widely accessible, AIM-informed nutritional support is already available.

Greycoat Dr. Toru – AIM-based support for kidney-related burden was formulated based on AIM research led by Dr. Toru Miyazaki. It is grounded in current scientific understanding of AIM biology and kidney health.

No supplement is intended to prevent or cure kidney disease. However, structured early support may help maintain overall balance over time.

Thank you for caring deeply about your cat’s kidney health.

Greycoat Research